Century Therapeutics Valuation
| IPSC Stock | USD 1.75 0.04 2.23% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. Century Therapeutics shows a prevailing Real Value of $2.14 per share. The current price of the firm is $1.75. Our model approximates the value of Century Therapeutics from analyzing the firm fundamentals such as Return On Equity of -0.14, profit margin of (0.23) %, and Current Valuation of 65.6 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Century Therapeutics' valuation include:
Price Book 0.8699 | Enterprise Value | Enterprise Value Ebitda 0.0752 | Price Sales 1.3496 | Enterprise Value Revenue 0.5788 |
Undervalued
Today
Please note that Century Therapeutics' price fluctuation is extremely dangerous at this time. Calculation of the real value of Century Therapeutics is based on 3 months time horizon. Increasing Century Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Century Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Century Stock. However, Century Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.75 | Real 2.14 | Target 3.5 | Hype 2.01 |
The real value of Century Stock, also known as its intrinsic value, is the underlying worth of Century Therapeutics Company, which is reflected in its stock price. It is based on Century Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Century Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Century Therapeutics helps investors to forecast how Century stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Century Therapeutics more accurately as focusing exclusively on Century Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Century Therapeutics' intrinsic value based on its ongoing forecasts of Century Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Century Therapeutics' closest peers. If more than one evaluation category is relevant for Century Therapeutics we suggest using both methods to arrive at a better estimate.
Century Therapeutics Cash |
|
Century Therapeutics Total Value Analysis
Century Therapeutics is currently projected to have valuation of 65.6 M with market capitalization of 152.96 M, debt of 53.83 M, and cash on hands of 378.76 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Century Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
65.6 M | 152.96 M | 53.83 M | 378.76 M |
Century Therapeutics Investor Information
About 26.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.87. Some equities with similar Price to Book (P/B) outperform the market in the long run. Century Therapeutics has Price/Earnings To Growth (PEG) ratio of 0.26. The entity recorded a loss per share of 0.32. The firm had not issued any dividends in recent years. Based on the key indicators related to Century Therapeutics' liquidity, profitability, solvency, and operating efficiency, Century Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.Century Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Century Therapeutics has an asset utilization ratio of 1.87 percent. This indicates that the Company is making $0.0187 for each dollar of assets. An increasing asset utilization means that Century Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Century Therapeutics Profitability Analysis
Based on Century Therapeutics' profitability indicators, Century Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Century Therapeutics' ability to earn profits and add value for shareholders.Net Loss | First Reported 2020-03-31 | Previous Quarter -32.5 M | Current Value -34.4 M | Quarterly Volatility 23.2 M |
For Century Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Century Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Century Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Century Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Century Therapeutics over time as well as its relative position and ranking within its peers.
Century Therapeutics Earnings per Share Projection vs Actual
By analyzing Century Therapeutics' earnings estimates, investors can diagnose different trends across Century Therapeutics' analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Century Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Century Therapeutics Ownership Allocation
The majority of Century Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Century Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Century Therapeutics. Please pay attention to any change in the institutional holdings of Century Therapeutics as this could imply that something significant has changed or is about to change at the company.Century Therapeutics Profitability Analysis
The company reported the previous year's revenue of 6.59 M. Net Loss for the year was (126.57 M) with profit before overhead, payroll, taxes, and interest of 7.99 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Century Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Century Therapeutics and how it compares across the competition.
About Century Therapeutics Valuation
The stock valuation mechanism determines Century Therapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Century Therapeutics. We calculate exposure to Century Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Century Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 5.9 M | 7.2 M | |
| Pretax Profit Margin | (17.04) | (17.90) | |
| Operating Profit Margin | (18.87) | (19.81) | |
| Net Loss | (17.29) | (18.15) |
Century Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Century Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Century we look at many different elements of the entity such as Century's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Century Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Century Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Century Therapeutics' worth.Complementary Tools for Century Stock analysis
When running Century Therapeutics' price analysis, check to measure Century Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Century Therapeutics is operating at the current time. Most of Century Therapeutics' value examination focuses on studying past and present price action to predict the probability of Century Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Century Therapeutics' price. Additionally, you may evaluate how the addition of Century Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |